O’Brien 2013.

Study characteristics
Methods	randomized, non‐blinded single center/United Kingdom
Participants	Study setting primary Eligibility criteria patients with suspected new NMIBC Non‐eligibility criteria suspicion of MIBC previous BCa porphyria pregnancy sensitivity 5‐ALA Intervention cohort participants recruited: 129 unifocal/multifocal tumors: 55/70/not stated: 4 Comparator cohort participants recruited: 120 unifocal/multifocal tumors: 36/79/not stated: 5
Interventions	Intervention: WLC + BLC followed by WL‐TURBT + BL‐TURBT Comparator: WLC followed by WL‐TURBT Adjuvant instillation therapy: 40 mg mitomycin C in 40 mL saline
Outcomes	Outcome(s) recurrence‐free survival Results median follow‐up: 12 months RFS rate at 12 months was 16% in intervention group and 22% in comparator group
Funding sources	NR
Declarations of interest	2 authors: speaker for GE Healthcare; 1 author: speaker for Photocure; 1 author: speaker for Ipsen
Contact of study author	Date of contact attempt to first study author: 30 November 2020 Contact status: no reply to date
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "randomization was performed in the urology department of Guy’s Hospital by means of sealed envelopes in blocks of 20" Comment: method of sequence generation clearly described
Allocation concealment (selection bias)	Low risk	Quote: "randomization was performed in the urology department of Guy’s Hospital by means of sealed envelopes in blocks of 20" Comment: allocation concealment clearly described
Blinding of participants and personnel (performance bias) Surgeon	High risk	Quote: NA Comment: surgeon unblinded
Blinding of participants and personnel (performance bias) Participants/study personnel	Unclear risk	Quote: NA Comment: unclear whether study participants and other study personnel were blinded
Blinding of outcome assessment (detection bias) Subjective outcomes (all outcomes)	Unclear risk	Quote: NA Comment: unclear whether study personnel were blinded
Incomplete outcome data (attrition bias) Oncological outcomes	Unclear risk	Quote: "excluded from follow‐up see figure 3" Comment: unclear rate (10% to 20%) of participants lost to follow‐up
Selective reporting (reporting bias)	Low risk	Quote: NA Comment: reporting according to the protocol (ISRCTN14275387) of primary outcome measure (recurrence rate of bladder tumor at 3 months and 12 months postsurgery) and secondary outcome measures (analysis of histology)
Other bias	Low risk	Quote: NA Comment: no other bias identified